Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

13 Dec 2019

Abstract excerpt

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to S100 Proteins and Annexins
Share to Thyroid Cancer Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31949496
DOI: 10.7150/jca.33105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancerPMID 31949496Read ↗

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapySemantic proximity Read ↗

The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer.Semantic proximity Read ↗

The Relevance between Iodine Nutritional Status and BRAFV600E Mutation on Papillary Thyroid CancerSemantic proximity Read ↗

BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposureSemantic proximity Read ↗

Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area.Semantic proximity Read ↗

Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.Semantic proximity Read ↗

[Advances in the research of BRAF(V600E) gene mutation correlated with papillary thyroid carcinoma].Semantic proximity Read ↗

BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?Semantic proximity Read ↗

[Application of BRAF in the diagnosis and treatment of thyroid papillary carcinoma].Semantic proximity Read ↗

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.Semantic proximity Read ↗

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.Semantic proximity Read ↗

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.